Alumis and Acelyrin have announced a definitive merger agreement, which will result in an all-stock transaction.

During March 2024, the Company sold a portion of its marketable securities for approximately $40,579,000, realizing net gains of $14,261,000, and used these proceeds and excess cash from ...